189 related articles for article (PubMed ID: 28236781)
1. Antipsychotic treatment and the Rorschach Perceptual Thinking Index (PTI) in psychotic disorder patients: Effects of treatment.
Biagiarelli M; Curto M; Di Pomponio I; Comparelli A; Baldessarini RJ; Ferracuti S
Psychiatry Res; 2017 May; 251():294-297. PubMed ID: 28236781
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the Rorschach Perceptual Thinking Index (PTI) and the Positive and Negative Syndrome Scale (PANSS) in psychotic patients: a validity study.
Biagiarelli M; Roma P; Comparelli A; Andraos MP; Di Pomponio I; Corigliano V; Curto M; Masters GA; Ferracuti S
Psychiatry Res; 2015 Feb; 225(3):315-21. PubMed ID: 25560479
[TBL] [Abstract][Full Text] [Related]
3. A psychometric evaluation of the Rorschach comprehensive system's perceptual thinking index.
Dao TK; Prevatt F
J Pers Assess; 2006 Apr; 86(2):180-9. PubMed ID: 16599792
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of psychotic from nonpsychotic psychiatric inpatients: the Rorschach Perceptual Thinking Index.
Benedik E; Čoderl S; Bon J; Smith BL
J Pers Assess; 2013; 95(2):141-8. PubMed ID: 23410237
[TBL] [Abstract][Full Text] [Related]
5. A comparison of new and revised Rorschach measures of schizophrenic functioning in a Serbian clinical sample.
Dzamonja-Ignjatovic T; Smith BL; Djuric Jocic D; Milanovic M
J Pers Assess; 2013; 95(5):471-8. PubMed ID: 23844937
[TBL] [Abstract][Full Text] [Related]
6. Assessment of disordered thinking in children and adolescents: the rorschach perceptual-thinking index.
Smith SR; Baity MR; Knowles ES; Hilsenroth MJ
J Pers Assess; 2001 Dec; 77(3):447-63. PubMed ID: 11781032
[TBL] [Abstract][Full Text] [Related]
7. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
[TBL] [Abstract][Full Text] [Related]
8. Disease and drug effects on internally-generated and externally-elicited responses in first episode schizophrenia and psychotic bipolar disorder.
Keedy SK; Bishop JR; Weiden PJ; Sweeney JA; Rosen C; Marvin R; Reilly JL
Schizophr Res; 2014 Oct; 159(1):101-6. PubMed ID: 25112158
[TBL] [Abstract][Full Text] [Related]
9. Rorschach inkblot method data at baseline and after 2 years treatment of consecutively admitted patients with first-episode schizophrenia.
Rosenbaum B; Andersen PB; Knudsen PB; Lorentzen P
Nord J Psychiatry; 2012 Apr; 66(2):79-85. PubMed ID: 21770830
[TBL] [Abstract][Full Text] [Related]
10. Differentiating psychotic patients from nonpsychotic patients with the MMPI-2 and Rorschach.
Dao TK; Prevatt F; Horne HL
J Pers Assess; 2008 Jan; 90(1):93-101. PubMed ID: 18444100
[TBL] [Abstract][Full Text] [Related]
11. Treatment of schizoaffective disorders.
Goodnick PJ; Meltzer HY
Schizophr Bull; 1984; 10(1):30-48. PubMed ID: 6142525
[TBL] [Abstract][Full Text] [Related]
12. Psychotic and Bipolar Disorders: Antipsychotic Drugs.
Holder SD; Edmunds AL; Morgan S
FP Essent; 2017 Apr; 455():23-29. PubMed ID: 28437058
[TBL] [Abstract][Full Text] [Related]
13. Acutely psychotic patients: a treatment approach.
Wagemaker H; Lippmann S; Cade JR
South Med J; 1985 Jul; 78(7):833-7. PubMed ID: 2861662
[TBL] [Abstract][Full Text] [Related]
14. Visual form perception: a comparison of individuals at high risk for psychosis, recent onset schizophrenia and chronic schizophrenia.
Kimhy D; Corcoran C; Harkavy-Friedman JM; Ritzler B; Javitt DC; Malaspina D
Schizophr Res; 2007 Dec; 97(1-3):25-34. PubMed ID: 17884347
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
[TBL] [Abstract][Full Text] [Related]
16. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.
McElroy SL; Dessain EC; Pope HG; Cole JO; Keck PE; Frankenberg FR; Aizley HG; O'Brien S
J Clin Psychiatry; 1991 Oct; 52(10):411-4. PubMed ID: 1938976
[TBL] [Abstract][Full Text] [Related]
17. Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders.
Deng H; Mohite S; Suchting R; Nielsen DA; Okusaga OO
Psychiatry Res; 2018 Mar; 261():248-252. PubMed ID: 29329043
[TBL] [Abstract][Full Text] [Related]
18. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
[TBL] [Abstract][Full Text] [Related]
19. Manic indices on the Rorschach.
Khadivi A; Wetzler S; Wilson A
J Pers Assess; 1997 Oct; 69(2):365-75. PubMed ID: 9392895
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic medication and the elderly.
Raskin DE
J Clin Psychiatry; 1985 May; 46(5 Pt 2):36-40. PubMed ID: 2859280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
